JOINTOWN PHARMACEUTICAL GROUP, a leading player in the pharmaceutical industry, is headquartered in China and operates extensively across various regions. Founded in 1995, the company has established itself as a key provider of high-quality pharmaceutical products and services, focusing on areas such as drug distribution, manufacturing, and research and development. With a diverse portfolio that includes prescription medications, over-the-counter products, and healthcare services, JOINTOWN is recognised for its commitment to innovation and quality. The company has achieved significant milestones, including strategic partnerships and expansions that enhance its market position. JOINTOWN PHARMACEUTICAL GROUP continues to set industry standards, making it a trusted name in healthcare solutions.
How does JOINTOWN PHARMACEUTICAL GROUP's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
JOINTOWN PHARMACEUTICAL GROUP's score of 24 is lower than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, JOINTOWN PHARMACEUTICAL GROUP reported total carbon emissions of approximately 47,929,410 kg CO2e, comprising 36,924,210 kg CO2e from Scope 1 emissions and 11,005,200 kg CO2e from Scope 2 emissions. This reflects their commitment to transparency in disclosing emissions data, although no Scope 3 emissions data has been provided. In the previous year, 2023, the company recorded significantly higher Scope 1 emissions at approximately 318,939,120 kg CO2e, indicating a potential focus on reducing operational emissions. However, there are currently no specified reduction targets or climate pledges outlined by JOINTOWN PHARMACEUTICAL GROUP, which suggests a need for further commitment to climate action. Overall, while JOINTOWN PHARMACEUTICAL GROUP has made strides in emissions reporting, the absence of reduction initiatives or targets highlights an opportunity for the company to enhance its climate commitments and align with industry standards for sustainability.
Access structured emissions data, company-specific emission factors, and source documents
2023 | 2024 | |
---|---|---|
Scope 1 | 318,939,120 | 00,000,000 |
Scope 2 | - | 00,000,000 |
Scope 3 | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
JOINTOWN PHARMACEUTICAL GROUP is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.